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The brain injury concept covers a lot of heterogeneity in terms of aetiology involving multiple factors, genetic, hemodynamic,
metabolic, nutritional, endocrinological, toxic, and infectious mechanisms, acting in antenatal or postnatal period. Increased
vulnerability of the immature brain to oxidative stress is documented because of the limited capacity of antioxidant enzymes and
the high free radicals (FRs) generation in rapidly growing tissue. FRs impair transmembrane enzyme Na+/K+-ATPase activity
resulting in persistent membrane depolarization and excessive release of FR and excitatory aminoacid glutamate. Besides being
neurotoxic, glutamate is also toxic to oligodendroglia, via FR effects. Neuronal cells die of oxidative stress. Excess of free iron and
deficient iron/bindingmetabolising capacity are additional features favouring oxidative stress in newborn. Each step in the oxidative
injury cascade has become a potential target for neuroprotective intervention. The administration of antioxidants for suspected
or proven brain injury is still not accepted for clinical use due to uncertain beneficial effects when treatments are started after
resuscitation of an asphyxiated newborn.The challenge for the future is the early identification of high-risk babies to target a safe and
not toxic antioxidant therapy in combination with standard therapies to prevent brain injury and long-term neurodevelopmental
impairment.
1. Introduction
The most common causes of neonatal brain injury in devel-
oping countries are extreme prematurity, neonatal stroke,
and hypoxic-ischemic encephalopathy (HIE) [1]. Extreme
prematurity leads to an increased risk of death or long-term
neurodevelopmental impairment including cerebral palsy
(CP) [2–4], but it also contributes to half of pediatric costs
for health care. The second and third trimesters represent
the most important period for brain development, with a
rapid increase in size, shape, and complexity [5]. Hypoxia-
ischemia, inflammation, and oxidative stress can lead to
an interruption of normal brain development especially
during this delicate period resulting in structural, biochem-
ical, and cell-specific injury [6]. The preoligodendrocytes,
which emerge and mature between 24 and 32 weeks of
development, are particularly susceptible to injury such
as intracranial hemorrhage, periventricular leukomalacia,
and other inflammatory conditions, and this damage can
result in white matter injury [7, 8]. Oxidative stress (OS)
plays a fundamental role in early injury, along with other
mechanisms such as excitotoxicity, to the neonatal brain.
OS in vivo is a degenerative process due to overproduction
of free radicals (FRs) (reactive oxygen species and reactive
nitrogen species) and propagation of their reactions. These
FRs include superoxide anion (O
2
−), hydroxyl radical (OH),
singlet oxygen (1O
2





cause damage to lipids, protein, andDNA, initiating a cascade
that results in cell death [9]. OS exists and tissue damage is
possiblewhen there are low levels of antioxidants or increased
FR activity [10]. Brain cells death at any age is primarily due
to hypoxia and energy depletion, followed by reperfusion
and FR overproduction. Excitotoxicity and nitric oxide (NO)
production are responsible of secondary energy failure and
delayed death. All these deleterious biological events trigger
the inflammatory response with cytokine production which
plays a major role in cell damage and loss. Local microglia
are activated, producing proinflammatory cytokines such as
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tumor necrosis factor- (TNF-) alpha, interleukin- (IL-) 1b,
and IL-6, as well as glutamate, FR, and NO, and are the main
immunocompetent cells in the immature brain [11].
Newborns and particularly preterm infants are at high
risk for OS and damage due to their organs’ structural
and functional immaturity with the lack of antioxidant
enzyme production, the overloading of aerobic metabolism
with rapidly growing energy demand, and the presence of
conditions leading to increased free iron levels with excessive
FR production.
Neonatal plasma has profoundly disturbed antioxidant
profiles with low levels of gluthatione peroxidase activity,
superoxide dismutase, 𝛽-carotene, riboflavin, 𝛼-proteinase,
vitamin E, selenium, copper, zinc, ceruloplasmin, transferrin,
and other antioxidant plasma factors [12].
In the developing fetus, hypoxia results in increased
anaerobic metabolism, leading to a rapid rise in levels of
lactic acid and reduced forms of electron transport chain
components in mitochondria, with subsequent FR overpro-
duction [13]. Other mechanisms contributing to reactive
oxygen FR formation and membrane lipid peroxidation
include phagocyte activation, metabolism of arachidonic
acid through the cyclooxygenase and lipoxygenase pathways,
reactions catalysed by increased free intracellular Fe++, and
increased xanthine oxidase activity as a result of increased
degradation of ATP [14]. Excess of free iron and deficient
iron/binding metabolising capacity are additional features
favouring OS in the premature infants [15]. The properties
and complex role of FR in the development of diseases make
antioxidant therapy very difficult to be realised particularly
because a critical aspect of protection is the prevention of
the hypoxic-ischemic insult which often happens already in
utero; thus prevention of intrauterine asphyxia is of great
relevance.
Insights into the biochemical and cellular mechanisms of
cellular injury with perinatal hypoxic-ischemic-reperfusion
insults provide a rational basis for formulation of interven-
tions to interrupt those mechanisms and thereby prevent or
ameliorate the injury.
Antioxidant substances may act at different phases of
the injury, decompartmentalizing metal complexes, limiting
FR production, modifying antiradical defenses, enhancing
intracellular or extracellular antioxidant levels, and incorpo-
rating lipophilic antioxidants into membranes or scavenging
superoxide [16]. Somedrugsmay inhibit phagocyte activation
or xanthine oxidase and arachidonic acid metabolism or
directly scavenge FR or repair FR-induced membrane injury,
like calcium antagonists and beta blockers. Elimination of
transition metals and especially nonprotein bound iron
(NPBI) is crucial for interrupting the formation of FR [17]
Figure 1.
Although many antioxidant agents have been shown to
be protective in animalmodels of hypoxia-ischemia, only few
substances have been used in pilot studies for newborns.This
paper highlights some of the important future therapeutics
for neuroprotection and describes which pharmacological
interventions can be considered to reduce brain injury in the
neonatal high risk population.
2. Vitamins C and E
Vitamins C and E are essential nutrients and are consid-
ered the most important antioxidants obtained through the
diet. The antioxidant actions of vitamin E (𝛼-tocopherol
and 𝛽-tocopherol) are due to its ability to be incorporated
into biological membranes to stabilize and protect against
lipid peroxidation [18], while the antioxidant properties of
vitamin C (ascorbic acid) arise from the ability to act as
electron donor, thereby preventing other agents from becom-
ing oxidized and quenching overproduction of FR. Studies
regarding the protective benefits of vitamins C and E in the
perinatal period are limited. Some in vitro evidences suggest
that, in adult and fetal rat brain cultures, vitamin E is able
to decrease lipid peroxidation and to increase survival and
neuritic extension of neurons [19, 20]. In vivo, prophylactic
administration of vitamin E before hypoxia-ischemia is able
to decrease the incidence of IVH [21]. Protective effects on
retinopathy of prematurity (ROP) have also been reported
with a reduction of ROP III+ from5.3 to 2.8% [22]. In amouse
model of Down syndrome, 𝛼-tocopherol suppresses lipid
peroxidation in the hippocampus and ameliorates behavioral
and cognitive impairments [23]. 𝛼-tocopherol has also been
shown to have anti-inflammatory properties. Administration
of 𝛼-tocopherol, particularly in large doses, has been shown
to decrease the release of proinflammatory cytokines from
cell lines exposed to lipopolysaccharide [24].
Ascorbate deficiency in the postnatal mouse brain (in the
presence of normal GSH levels) leads to diminished motor
functions, yet an exaggerated response to a dopaminergic
agonist [25]. Ascorbate antioxidant effects are enhanced in
conjunction with vitamin E. When vitamin E is oxidized, it
forms 𝛼-tocopherol radical which is harmful, but vitamin C
is able to mediate the return of 𝛼-tocopherol radical to 𝛼-
tocopherol, thus regenerating𝛼-tocopherol concentrations in
plasma [26]. In support of these findings, a study of transient
intrauterine ischemia in pregnant rats showed that either
vitamin E or vitamin C treatment alone, started before the
ischemic insult, was able to decrease oxidative mitochondrial
impairment in the fetal brain, but the improvement was
greater when vitamins were administered together [27].
On a cautionary note vitamin C has both prooxidant
or antioxidant effects in vitro; it is able to inhibit protein
synthesis and induce late neuronal death [28–30]. Similarly,
vitamin E may induce apoptosis in absence of OS [31],
potentially limiting its protective effects only to situations
when OS is established. It is hypothesized that protecting the
fetus through the pretreatment of the mother could in itself
be beneficial andwithout any additional risk burden on either
the mother or her baby, although the possibility of toxicity of
these agents in absence of OS was also postulated.
3. Inhibitors of NOS
Nitric oxide (NO) is a free radical that is formed in high
concentrations during and after hypoxia-ischemia. Three
enzymes especially upon reperfusion and reoxygenation after
perinatal HI can catalyze the formation of NO: neuronal
NOS (nNOS), inducible NOS (iNOS), and the endothelial
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Figure 1: Oxidative stress pathways and the possible antioxidant drugs targets.
NOS (eNOS) [32] that are all expressed in the brain in
neurons, astrocytes, and endothelial cells and can be induced
in microglia. eNOS is thought to have a neuroprotective
function via enhancing perfusion of the brain if necessary
[33, 34].
NO can react with superoxide to form peroxynitrite,
which can cause nitration of proteins, predominantly on
tyrosine residues contributing to further damage to brain
tissue [35]. Selective inhibition of nNOS and iNOS with
the nNOS inhibitor, 7-nitroindazole, and the iNOS inhibitor
aminoguanidine have been proved to be promising as neuro-
protectants in neonatal rats [36–38].
The pharmacologic inhibition of nNOS, or its genetic
deletion, confers neuroprotection in animal models of tran-
sient cerebral ischemia [38, 39]. Iminobiotin inhibits both
the neuronal and inducible isoforms of nitric oxide synthase.
Otherwise, in vivo, it provides neuroprotection probably
hindering apoptotic pathways. Nijboer et al. demonstrated
that treatment with 2-iminobiotin provided gender specific
long- and short-term neuroprotection in female newborn
rats with hypoxia-ischemia via inhibition of the cytochrome
c-caspase 3 neuronal death pathway [40]. However, only
female and not male animals were protected against post-
HI reperfusion damage to the brain [41, 42]. Moreover, the
existing evidence suggests that the in vivo neuroprotective
effect of 2-iminobiotin was not dependent on nNOS/iNOS
inhibition [41, 43]. The exact mechanism of action of 2-IB
remains to be determined, but it is clear that in females
neuroprotection is associated with reduced activation of the
apoptotic pathways.
4. Allopurinol
Allopurinol and its metabolite oxypurinol are inhibitors of
xanthine oxidase, the enzyme involved in superoxide produc-
tion especially during reperfusion damage. Allopurinol has
also additional effects, directly scavenging the toxic hydroxyl
free radical and mainly chelating the nonbound protein
iron (NBPI), particularly at high doses [44]. Allopurinol is
converted into oxypurinol, which crosses the blood brain
barrier more easily. Palmer et al. were the first to recognize
the neuroprotective properties of allopurinol in a neonatal rat
model of HI brain injury [45]. The data of this study were
promising, although another study was less positive on the
neuroprotective potential of allopurinol [46]. In asphyxiated
infants who received allopurinol, NO serum level decreased
significantly from 24 hours to 72–96 hours after birth [47].
The treated newborns had also better neurodevelopmental
outcomes. In other studies in humans allopurinol was not
seen to improve short-termor long-termoutcomes after birth
asphyxia [48]. In a pilot study, Torrance et al. administrated
to 53 pregnant women in labor (54 fetuses with a gesta-
tional age >36 weeks and signs of fetal hypoxia) 500mg of
allopurinol or placebo intravenously. They found a reducing
effect on biomarkers of neuronal damage and NPBI [49].
It is possible that allopurinol has no positive effect when
administered late and at low doses [50]. It was hypotesized
that the drug needed to be administrated before the start of
reperfusion injury, so trials are now underway to evaluate
efficacy when given to mothers who have fetuses suspected
of intrauterine hypoxia [8]. In a randomized, double-blind,
placebo-controlled multicenter study that is now in progress,
intravenous allopurinol is being given antenatally with the
primary outcome being serumbrain damagemarkers (S100b)
and oxidative stress markers (isoprostanes and so forth) in
umbilical cord blood, while secondary outcome measures
are neonatal mortality, serious composite neonatal morbid-
ity, and long-term neurologic outcome [51]. There is now
a randomized, placebo-controlled, double-blinded parallel
group comparison study of hypothermia and allopurinol
ongoing (the European ALBINO Trial). Allopurinol is being
given twice: 30 minutes after birth and then 12 hours later,
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in addition to hypothermia in moderate to severe HIE.
Outcomes will be assessed at 2 years of life. Kaandorp
and colleagues found no differences in long-term outcome
between the allopurinol-treated infants with moderate to
severe birth asphyxia and controls. However, subgroup analy-
sis of the moderately asphyxiated group showed significantly
less severe adverse outcome in the allopurinol-treated infants
compared with controls (25% versus 65%; RR 0.40, 95%CI
0.17 to 0.94), suggesting a protective effect of neonatal
allopurinol treatment inmoderately asphyxiated infants [52].
5. Erythropoietin
Erythropoietin (Epo) and its receptor (EpoR) are expressed in
several types of cells including astrocytes and microglial cells
of the developing central nervous system and are required
for normal brain development [53]. The acute exposure to
hypoxia upregulates the expression of EpoR on oligoden-
drocytes and neurons, without a similar increase in Epo
expression [54].Thepresence of unboundEpoRdrives cells of
neuronal and oligodendrocyte lineage to apoptosis, whereas
ligand-bound EpoR activates survival signaling pathways
[55]. The signalling cascade activated by Epo is able to block
early mechanisms of brain injury by its antiinflammatory,
antiexcitotoxic, antioxidant, and antiapoptotic effects on
neurons and oligodendrocytes [56–58]. Erythropoietin (Epo)
is directly involved in the prevention of OS with generation
of antioxidant enzymes, inhibition of nitric oxide production,
and decrease of lipid peroxidation [59]. Moreover, Epo can
decrease the production of proinflammatory cytokines and
of the associated apoptotic injury, as it happens in adult
stroke and neonatal models of hypoxia-ischemia treated
with rEPO [57, 60]. Higher circulating Epo concentrations
might produce more benefits than lower concentrations [61].
In addition the beneficial effects are dose dependent, with
multiple doses being more effective than single doses [62]
even when initiated 48 to 72 hours after injury reducing
neuronal loss and learning impairment [63, 64]. Epo is now
under investigation for both term and preterm brain injuries,
being effective in reducing brain injury in both groups and it
is approved by the US Food and Drug Administration with a
robust safety profile in neonates.
The specific effects of Epo in preoligodendrocytes may
be most relevant to the white matter injury that character-
izes preterm brain injury [8]. Treatment approaches should
be differentiated in case of proven brain injury (HIE of
term infants and IVH in preterm infants) and preventative
strategies in preterm infants. In the first case (brain injury)
a shorter duration of high-dose Epo is most appropriate,
whereas a more prolonged treatment strategy that continues
during the period of oligodendrocyte maturation is most
likely to succeed for preventative purposes. Furthermore, this
more prolonged treatment also decreases the availability and
potential toxicity of free iron, caused by the erythropoietic
effects of Epo, by increasing iron utilization [8].
In addition, the impossibility of Epo to cross the placenta
makes the prenatal treatment unavailable even if some new
studies suggest that a dose of 500mg intravenous allopurinol
rapidly crosses the placenta and provides target concentra-
tions in 95% of the fetuses at the moment of delivery, which
makes it potentially useful as a neuroprotective agent in
perinatology [65, 66].
Doses of 1000 to 5000U/kg were effective for neuropro-
tection in animal models of neonatal brain injury, improving
both short-term and long-term structure and function [67].
Phase I/II trials on human newborns [68–70] suggested
1000U/kg/dose as the optimal dose. Phases II and III studies
are now ongoing in both preterm and HIE term infants. Epo
is also being studied in combinationwith hypothermia for the
treatment of HIE in term infants. Adjunctive use of Epo com-
bined with hypothermia in nonhuman primates subjected to
umbilical cord occlusion was showed to improve motor and
cognitive responses, cerebellar growth, and diffusion tensor
imaging measures, producing death/disability relative and
absolute risk reduction [71, 72]. Conversely, in a rat model
of hypoxia-ischemia, no significant benefit or, at least, only a
borderline additive neuroprotective effect of EPO combined
with hypothermia was observed [73, 74].
In various experimental models, Epo demonstrates a
neuroprotective effect particularly after neuronal damage
related to ischemia-reperfusion events. Early treatment after
HI with a high dose of Epo (5000U/kg) reduces tissue loss,
preserving brain volume [62], and enhances neurogenesis,
probably through a shift from astrocytic to neuronal cell fate
[75].
A therapeutic strategy with lower multiple Epo doses,
such as 1000U/kg, did not result in significant neuropro-
tection from early neuronal damage, even when combined
with deferoxamine, an iron chelator which has been shown
to decrease OS [76].
A randomized prospective study reported that repeated,
low doses (300 or 500U/kg every day) of Epo were safe and
resulted in improved neurological outcome for patients with
moderate neonatal HIE at 18 months of age [77]. Recently, in
an analysis of secondary outcomes of a randomized clinical
trial of preterm infants, high-dose erythropoietin treatment
(3000 IU/kg) within 42 hours after birth was associated with
a reduced risk of brain injury on MRI [72].
A high survival rate with no or minor cerebral sequelae
was observed in adult patients treated with hypothermia and
early high doses of Epo therapy (40 000 IU) for the first 48 h,
soon after resuscitation from cardiac arrest, in a small pilot
study [78]. Safety concerns appeared from some adult Epo
trials reporting adverse effects related to vascular thrombosis,
intracerebral hemorrhage, and brain edema [79].
6. Albumin and Docosahexaenoic Acid (DHA)
Albumin is the main protein of plasma, representing about
60% of all plasma proteins. Marzocchi et al. demonstrated
albumin carbonylation in newborns with higher NBPI levels
and poor neurodevelopmental outcome [80]. Since NBPI
may produce hydroxyl radicals through the Fenton reaction,
the major target of OS induced by NBPI is its carrier,
albumin. As albumin is a major extracellular antioxidant,
its susceptibility to oxidation can be expected to decrease
plasma antioxidant defenses and increase the likelihood of
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tissue damage due to OS in the newborn. Nitrated albumin
was found significantly increased in patients who developed
moderate or severe encephalopathy compared to those who
had a normal neurological evolution or developed mild
encephalopathy [81]. There is evidence that albumin signif-
icantly enhances neurological function and may decrease
brain edema and infarction if administered 4 hours after
ischemia occurrence in adult rats [82]. In clinical trials it
was observed that administration of albumin may cause side
effects on lungs [83]. To reduce this side effect, albumin in low
doses may be administered in association with docosanoids.
Docosanoids are derivates of docosahexaenoic acid (DHA),
which is a major product of the oxidative lipid degradation
of the membrane after cerebral ischemia; its bioproducts can
inhibit the infiltration of leukocytes and reduce expression
of NF-𝜅B. DHA treatment before the insult confers neu-
roprotection in a rat model of cerebral hypoxia-ischemia
[84]. DHA improves function without affecting brain volume
loss in a rat model of hypoxia-ischemia and inflammation
induced perinatal brain injury [85].
7. Deferoxamine
Deferoxamine is a chelating agent and its target is the
formation of hydroxyl radicals from free iron during reper-
fusion. Deferoxamine can cross the blood brain barrier and
chelate NBPI, thus reducing the severity of brain injury and
improving cerebral metabolism in animalmodels of hypoxia-
ischemia [86]. Deferoxamine treatment in lambs limited the
hypoxia-ischemia induced NBPI increase in plasma and in
cortical tissue [87]. Negative effects on hemodynamics when
administrated at high doses in preterm baboons have been
observed [88]. Several experimental studies have been per-
formed in newborn animals of various species including pigs
and rats with positive results [89, 90]. Up to now, however,
free ion chelators have never been tested in newborn babies
to treat reperfusion/reoxygenation injury after perinatal HI.
8. Prostaglandins Inhibitors
The inhibition of prostaglandin productionwas hypothesized
to be another important target to fight post-HI brain damage
in the newborn. Indomethacin is a cyclooxygenase inhibitor
and has been shown to reduce neonatal brain damage after
perinatal HI in experimental studies [91]. Indomethacin is
used in preterm babies to reduce or prevent the occurrence
of periventricular/intraventricular hemorrhages [92, 93] and
can reduce white matter injury in preterm infants [91, 94, 95].
It has not been experimented yet in the term infant to reduce
reperfusion/reoxygenation injury of the brain after perinatal
HI.
9. Magnesium Sulphate
Magnesium is essential for key cellular processes, like gly-
colysis, oxidative phosphorylation, proteins synthesis, and
DNA and RNA aggregation [96]. Moreover magnesium can
influence mechanisms implicated in cell death due to the
production of proinflammatory cytokines during the inflam-
matory response and, through the noncompetitive voltage
dependent inhibition of the NMDA-type glutamate receptor,
it can reduce calcium entry in the cells leading to the preven-
tion of the excitotoxic calcium induced injury [97]. Recent
evidences demonstrate that fetal exposure to magnesium
sulfate in women at risk for preterm delivery significantly
reduces the risk of cerebral palsy without increasing the
risk of death [98–100]. In adult rats with cerebral ischemia,
magnesium sulfate was demonstrated to be more effective,
increasing neuronal survival rate, than either treatment used
alone [92]. Most of the positive evidence with magnesium
sulfate is for the preterm population [93]; preclinical and
clinical evidence for magnesium sulfate in term hypoxia-
ischemia are less good than other approaches [101–103]; and
term infants may have significant risk of hypotension at high
doses [104]. Magnesium has other important side effects:
it can provoke haemodynamic instability, bradycardia, and
delayed intraventricular conduction, including complete atri-
oventricular block [105]. It appears that magnesium sulfate is
ineffective in delaying birth or preventing pretermbirthwhen
used as a tocolytic [106]. Furthermore, high cumulative doses
ofmagnesium sulfatemay be associated with increased infant
mortality [107]. The evidence to date confirms the efficacy
of magnesium sulfate therapy for women with eclampsia
and preeclampsia and for reduction of cerebral palsy in the
setting of threatened preterm delivery. However, magnesium
sulfate should not be used as a tocolytic for preterm labor.
A recent review from Galinsky and colleagues suggested
the inconsistent histopathological impact of treatment both
before and after the hypoxic-ischemic insult, likely related to
the lack of temperature control during and after HI, along
with variability in the dose, timing of treatment, and survival
time after the insult [108].These findings strongly suggest that
clinical trials of MgSO
4
for encephalopathy at term would be
premature, despite the very promising results from studies of
global or focal ischemia in adult rodents. These observations
suggest a need for further testing in animal models of HIE
before magnesium should be considered for trials in humans
as a potential adjunct therapy with hypothermia.
10. N-Acetylcysteine
N-Acetylcysteine (NAC) is a scavenger of oxygen radicals and
restores intracellular glutathione levels, attenuating reperfu-
sion injury and decreasing inflammation and nitric oxide
(NO) production in adult models of stroke [109]. It has low
toxicity and it is able to cross the placenta and the blood-brain
barrier. In most experiments to evaluate neuroprotective
effects of NAC, repeated administration has been used. In
an animal model of hypoxia-ischemia, NAC treatment com-
bined with systemic hypothermia prevented brain tissue loss,
with increased myelin expression and improved the short-
term functional outcomes of labyrinthine and cerebellar inte-
gration [110]. Consistently with this, Cakir et al. reported that
after spinal cord ischemia, NAC and hypothermia alone were
associated with limited protective effects, whereas the combi-
nation ofNAC and hypothermia resulted in highly significant
recovery of spinal cord function [111]. NAC may also have
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anti-inflammatory effects, by reducing intracerebral levels of
tumor necrosis factor-𝛼, interleukin-1𝛽, and inducible NO
synthase, when administered in pregnant female rats 2 h
before the administration of endotoxin lipopolysaccharide
[112]. Intraperitoneal treatment of pregnant rats with NAC
(50mg/kg) attenuated LPS-induced expression of inflamma-
tory mediators in fetal rat brains and prevented postnatal
hypomyelination [112]. NAC administered to pregnant rats
in their drinking water (500mg/kg/day), from E17 to birth,
prevented LPS-induced oxidative stress in the hippocampus
of male fetuses and restored long-term potentiation in the
hippocampus and improved spatial recognition performance
in male off-spring [113]. Posttreatment with NAC, 4 hours
after the LPS challenge, prevented loss of glutathione in
hippocampus and improved spatial learning deficits [114].
Furthermore, NAC induced marked neuroprotection, asso-
ciated with improvement of the redox state and inhibition of
apoptosis after LPS-sensitized hypoxic-ischemic brain injury
in neonatal rats [115]. After neonatal hypoxia-reoxygenation
in piglets, NAC reduced cerebral oxidative stress with
improved cerebral oxygen delivery and reduced caspase-
3 and lipid hydroperoxide concentrations in cortex [116].
Similarly, hypoxia-reoxygenation-induced cortical hydrogen
peroxidase was reduced with NAC therapy [117]. In fetal
sheep, NAC exacerbated LPS-induced fetal hypoxemia and
hypotension and induced polycythemia [118]. In a random-
ized clinical trial on preterm newborns, therapy with NAC
by continuous infusion during the first 6 days after birth did
not change the incidence of periventricular leukomalacia or
intraventricular hemorrhage, in the treated babies [119]. In
addition, NAC is also associated with adverse reactions that
limit its use in humans, particularly anaphylactic reactions,
including rash, pruritus, angioedema, bronchospasm, tachy-
cardia, and hypotension, usually occurring within 2 hours of
the initial infusion [120].
11. Melatonin
Melatonin is the main product of the pineal gland, with
high antioxidant and anti-inflammatory properties [121, 122]
and is synthesized starting from tryptophan [123]. When
synthesized, it is quickly released in all biological fluids such
as bile, cerebrospinal fluid [124], blood, saliva [125], semen
[126], and amniotic fluid [127] and it functions as time-
giver in the regulation of the circadian rhythm [128]. This
rhythm inmammals is generated by an endogenous circadian
master clock located in the suprachiasmatic nucleus of the
hypothalamus. It participates in several neuroendocrine and
physiological processes and is considered also a tissue factor,
a paracoid, an autocoid, an antioxidant and sometimes a
hormone depending on its physiological actions. Melatonin
has a broad-antioxidant spectrum, a direct or indirect effect,
and an anti-inflammatory property [129, 130]. It is partic-
ularly interesting for its ability to cross all physiological
barriers [131] and to be widely distributed in tissues, cells, and
subcellular compartments. Working as a direct antioxidant,







andONOO−, and as an indirect one it induces the production
of antioxidant enzymes, including glutathione peroxidase,
glutathione reductase, glucose-6-phosphate dehydrogenase,
and superoxide dismutase and increases the efficiency of
mitochondrial electron transport [132–134].
Particularly its ability to scavenge the dangerous “∙OH”
is much higher than other antioxidants including mannitol,
glutathione, and vitamin E [135, 136]. Moreover, melatonin
has no prooxidant effects unlike many other antioxidants
and does not interfere with the thrombolytic and neuro-
protective actions of other drugs [137, 138]. In addition
melatonin can inhibit the expression of adhesion molecules
therefore curbing PMN infiltration and tricking the cascade
of inflammation [121]. Moreover melatonin may inhibit the
NF-𝜅B expression, which is a nuclear transcription factor
involved in inflammation development by interacting with
its receptor MT1. Blocking NF-𝜅B melatonin acts as an
anti-inflammatory molecule through the inhibition of the
biochemical events following NF-𝜅B activation, such as the
NO and prostaglandins production by iNOS and COX-2
[139]. Melatonin could be a useful drug in preterm deliv-
ery, a condition highly susceptible to OS injury due to
the need of oxygen use for neonatal resuscitation and to
the immaturity of the antioxidant systems. Because of its
lipophilic properties,melatonin easily crossesmost biological
cell membranes, including the placenta and the blood-brain
barrier. Unfortunately, despite its anti-inflammatory and
antioxidant functions, melatonin is not currently available
for neonatal therapeutic trials and a neonatal intravenous
formulation needs to be developed. It is still unclear how
much melatonin is absorbed after oral or rectal doses in
infants who have been cooled and asphyxiated, but when
it was used as a compassionate drug in neonatal asphyxia,
preliminary findings supported the possibility for its wider
evaluation in perinatal medicine [140]. Other studies found
also that melatonin administration after HI in immature
rats has an excellent and long-lasting benefit on ischemic
outcomes and could represent a potentially safe approach
to perinatal brain damage in humans [141]. Post ischemia
intraperitoneal administration of melatonin significantly
protected the brain from injury and reduced infarct volume,
mainly in the hippocampus and cerebral cortex. Melatonin
treatment also improved functional recovery into adulthood
[141]. The optimal neuroprotective dose still needs to be
determined, although a 5-mg/kg infusion for 6 hours started
10 minutes after resuscitation and repeated at 24 hours
augmented hypothermic neuroprotection in the newborn
piglet [121].
Even if there are no studies on antenatal administration
of melatonin, animal studies indicate that even doses as
high as 200mg/kg for several days during pregnancy in rats
do not have toxic effects on either mother or fetus [142].
When administered directly to the sheep fetus after umbilical
cord occlusion, melatonin attenuated the production of 8-
isoprostanes and reduced the number of activated microglia
cells and terminal deoxynucleotidyl transferase dUTP nick
end labeling- (TUNEL-) positive cells in the brain [121].
In addition maternal administration prevented subsequent
increase in free radical production in fetal sheep exposed
to intrauterine asphyxia [143]. Maternal melatonin admin-
istration at the end of pregnancy reduced signs of cerebral
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inflammation and apoptosis after birth asphyxia in the spiny
mouse [144]. When given in low doses (0.005–5mg/kg i.p.),
melatonin reduced brain lesions in the white matter >80%,
and melatonin was still (but less) effective when given 4
hours after the insult and reduced learning deficits [145]. It
was also shown how melatonin protected the cerebral white
matter after 2 hours of hypoxic insults in newborn rats [146],
decreased microglial activation and astroglial reaction, and
promoted oligodendrocyte maturation in growth restricted
rat pups [147]. Finally a recent observational study showed
that preterm and term newborn infants are deficient in
melatonin levels, and it is now being trialed daily for 7
days after premature birth to identify whether it will reduce
the risk of prematurity-associated brain injury (MINT;
ISRCTN15119574, 2014). Another investigation is underway
in premature and full-term babies to identify optimal treat-
ment doses. An Australian study evaluating melatonin to
prevent brain injury in unborn growth-restricted babies is
ongoing in which mothers receive melatonin during preg-
nancy and OS is monitored in maternal serum, placenta,
and umbilical cord blood (NCT01695070, 2014). Based on
all these data, melatonin is a well-documented multifunc-
tional molecule that may be a useful therapeutic agent for
the treatment of neonatal hypoxic-ischemic encephalopathy.
Melatonin is safe, nontoxic, and available in pure form for
human use. These results of animal experimental models
and human case reports provide fundamental information on
the need of and the potential usefulness of clinical trials to
evaluate melatonin as a neuroprotective drug.
12. Lutein
Lutein belongs to the family of carotenoids. Studies con-
ducted both in vitro and in vivo have identified several
properties of lutein, showing a defensive action that occurs
through the neutralization of FR and singlet oxygen. Studies
report that lutein is able to reduce the risk of developing
some ocular diseases or slow down their progression [148].
Lutein may play a role in tissues defense through a func-
tional mechanisms using the phenomenon of deactivation
(quenching) of singlet oxygen and of reactive oxygen species
[149], protecting the retina from ischemic/hypoxic damage
by its antioxidative, antiapoptotic, and anti-inflammatory
properties [150]. Lutein and its isomer zeaxanthin in the
macular pigmentmay play an important role in protecting the
eyes of the newborn from the damage of light thanks to their
ability to absorb blue light and their antioxidant action [151].
Lutein administration in newborns increases the levels of bio-
logical antioxidant potential (BAP), decreasing OS markers
levels in healthy term newborns, suggesting potential for its
testing in clinical trials to protect newborns from perinatal
OS [152, 153]. There was also a difference between breastfed
and formula fed infants. Breastfed infants had higher mean
serum lutein concentrations than infants who consumed
formula unfortified with lutein. These data suggested that
approximately four times more lutein is needed in infant
formula than in human milk to achieve similar serum lutein
concentrations among breastfed and formula fed infants
[154]. Manzoni et al. found no treatment-related adverse
effect in 229 preterm infants supplemented with lutein. They
found no significant differences in the threshold of ROP
between treated versus not treated infants [155]. The same
occurred for NEC and BPD. Interestingly they found that
the progression rate from early ROP stages to threshold ROP
was decreased by 50% [155] showing how lutein/zeaxanthin
supplementation in preterm infants is well tolerated and can
interfere with ROP progression. Rubin et al. assessed lutein
safety and they demonstrated that supplemented infants had
lower plasma C-reactive protein and that plasma lutein levels
correlated with the full field electroretinogram-saturated
response amplitude in rod photoreceptors in a cohort of
203 preterm newborns. Finally the supplemented group also
showed greater rod photoreceptor sensitivity [156]. All these
data suggest that lutein may be a promising drug against
oxidative injury.
13. Dietary Supplements
Dietary supplements may also be promising in neuropro-
tection. Pomegranate juice is rich in polyphenols that was
proven to protect the neonatal mouse brain against an
HI insult when given to mothers in their drinking water
[157]. A substantial protection in hippocampus, cortex, and
striatum was observed even when given after the insult to
neonatal animals [158]. Omega-3 polyunsaturated fatty acid
supplementation can reduce brain damage and improve long-
159 neurologic outcomes even 5 weeks after an HI insult to
rodents [159].
14. Conclusions
Even if there are still gaps in knowledge about antiox-
idants and their role in neuroprotection, progress has
been made in this field. Probably a combination of these
drugs and supplements should be more extensively inves-
tigated in order to reduce brain injury to the develop-
ing neonate. The relationship between FR production and
brain injury is complex. Clearly FR damage results from
hypoxia, ischemia-reperfusion, neutrophil and macrophage
activation, Fenton reaction, endothelial cell xanthine oxidase,
phospholipid metabolism, nitric oxide, mitochondrial oxida-
tive metabolism impairment, and proteolytic pathways. Each
step in the oxidative injury cascade has become a potential
target for neuroprotective intervention. The administration
of antioxidants for suspected or proven brain injury is still
not accepted for clinical use due to uncertain beneficial
effects when treatments are started after resuscitation of an
asphyxiated newborn.The challenge for the future is the early
identification of high-risk babies to target a safe and not toxic
antioxidant therapy in combination with standard therapies
to prevent brain injury and long-term neurodevelopmental
impairment.
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